Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 15;17(10):3469.
doi: 10.3390/ijerph17103469.

Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp-A Usability Study

Savino Sciascia  1 , Massimo Radin  1 , Irene Cecchi  1 , Pierluigi Di Nunzio  2 , Nicola Buccarano  2 , Federico Di Gregorio  2 , Milone Valeria  3 , Sara Osella  3 , Paola Crosasso  3 , Marika Denise Favuzzi  1 , Elena Rubini  1 , Silvia Grazietta Foddai  1 , Simone Baldovino  1 , Dario Roccatello  1 , Daniela Rossi  1
Affiliations

Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp-A Usability Study

Savino Sciascia et al. Int J Environ Res Public Health. .

Abstract

Objective: To create a mobile application able to help patients follow medical treatments properly.

Methods: We designed and developed a custom Android/iOS App to remind patients of the pharmaceutical drugs to be taken, of the visits and exams to attend, and to detect their compliance with their personal therapeutic plan. In this paper we describe the App development, UX/UI design, Gamification. TuTOR is an Android and iOS application designed to remind patients of the drugs to be taken, giving them all the information related to their therapeutic plans in a simple and non-invasive way. Thanks to a dedicated back-office, specially designed to meet specific medical information needs, the App can also help physicians detect their patients' compliance with their treatments and modify prescriptions in real time. The App also ensures a state-of-the-art approach to data security and privacy protection. The main feature of TuTOR is the smart therapy assistant, which features dedicated alarms to remind users of taking their prescription drugs. Thanks to the automatic synchronization with a local database, the alert system works even without connection to the Internet. Particular attention was paid during the App's design process: we looked to create an intuitive interface to ensure absolute ease of use, with state-of-the-art visual design aimed at maximizing user experience. Other relevant features include the App's ability to givevisual evidence of the most important drugs to be taken and its note-taking feature, which gives patients the possibility to note down indications on why a specific drug was skipped. The App also keeps track of upcoming medical exams, laboratory tests, and visits on a devoted calendar. It also helps patients by listing therapy contacts, such as physicians' phone numbers, and indicates all medical references by showing, for example, locations of relevant clinics and pharmacies on a map. Thanks to specific visual progress indicators and an innovative gamification approach, the App encourages users to faithfully follow therapy guidelines. With TuTOR, assessing the therapy's state of completion is quick and easy.Thanksto the privacy-by-design approach used, all data managed by the system is compliant with the European Privacy Regulation and it is not available to third parties.

Expected results: A mobile App for medication adherence might increase objectively and subjectively measured adherence.

Keywords: UX/UI design; gamification; mobile application; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Medical plan in the TuTOR mobile App.
Figure 2
Figure 2
Clinical follow-up plan in the TuTOR mobile App.
Figure 3
Figure 3
Timeline of the research protocol of the study.
Figure 4
Figure 4
Back-office of the TuTOR App.
See this image and copyright information in PMC

References

    1. Wiens A., Venson R., Correr C.J., Otuki M.F., Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339–353. doi: 10.1592/phco.30.4.339. - DOI - PubMed
    1. Hahn B.H., McMahon M.A., Wilkinson A., Wallace W.D., Daikh D.I., Fitzgerald J.D., Karpouzas G.A., Merrill J.T., Wallace D.J., Yazdany J., et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. (Hoboken) 2012;64:797–808. doi: 10.1002/acr.21664. - DOI - PMC - PubMed
    1. Smolen J.S., Landew R., Bijlsma J., Burmester G., Chatzidionysiou K., Dougados M., Nam J., Ramiro S., Voshaar M., van Vollenhoven R., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 2017;76:960–977. doi: 10.1136/annrheumdis-2016-210715. - DOI - PubMed
    1. Burmester G.R., Blanco R., Charles-Schoeman C., Wollenhaupt J., Zerbini C., Benda B., Gruben D., Wallenstein G., Krishnaswami S., Zwillich S.H., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet. 2013;381:451–460. doi: 10.1016/S0140-6736(12)61424-X. - DOI - PubMed
    1. Fleischmann R., Kremer J., Cush J., Schulze-Koops H., Connell C.A., Bradley J.D., Gruben J.D., Wallenstein G.V., Zwillich S.H. Placebo-Controlled Trial of TofacitinibMonotherapy in Rheumatoid Arthritis. N. Engl. J. Med. 2012;367:495–507. doi: 10.1056/NEJMoa1109071. - DOI - PubMed

Publication types